Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILES 5 – Durvalumab vs chemotherapy in elderly advanced NSCLC
2024-515326-83-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jul 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoints: 12-month overall survival and 4-month mortality rate. Planned start Jul 2018; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515326-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515326-83-00.